chf treatment :: Article Creator Novartis' Entresto Set To Transform Heart Failure Treatment – And Maybe Pricing Too Novartis' head of medical affairs Ameet Nathwani talks about the remarkable story of Entresto's accelerated development, and plans for a novel pricing. As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very impressive data. The Food and Drug Administration approved Entresto (sacubitril/valsartan) last week, licensing it to reduce the risk of cardiovascular death and hospitalisation in patients with chronic heart failure, following a priority review. The approval is based on the 8,442-patient PARADIGM-HF study, the largest ever conducted in heart failure. In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the r...